title: [Parathyroid hormone in the treatment of osteoporosis].
abstract: Current treatments available for osteoporosis until recently were active by inhibiting osteoclast activity and, thus, reducing bone remodelling. Intact PTH (PTH 1-84) and its analog, teriparatida (human recombinant PTH 1-34), are a new class of anabolic treatment of osteoporosis. It has been described a positive effect on bone microarchitecture and a reduction of the risk of new fractures due to a bone-forming mechanism.PTH must be considered as an useful alternative in the treatment of severe osteoporosis, both in men and women, in patients with several osteoporosis-related fractures or with a very low bone mineral density (T-score below -3.5) an a high risk for fracture. Other potential uses are glucocorticoid-induced and other secondary osteoporosis. The use of PTH is not recommended for more than 18 months for teriparatida and 24 months for PTH 1-84.
authors.affiliation: Universidad de Las Palmas de Gran Canaria, Grupo de Investigación en Osteoporosis. msosa@ono.com
authors.forename: M
authors.initials: M
authors.lastname: Sosa Henríquez
authors.forename: A
authors.initials: A
authors.lastname: Díez Pérez
mesh_terms: D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000627:therapeutic use*
chemical_list: D010281:Parathyroid Hormone